Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21477710 | 0.99 | FAP (0.44) | FAPSIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL19046493 | 0.99 | FAP (0.44) | FAPSIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL21897649 | 0.99 | FAP (0.44) | FAPSIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL20841072 | 0.99 | FAP (0.44) | FAPSIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL18937600 | 0.99 | FAP (0.44) | FAPSIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL23789219 | 0.99 | FAP (0.44) | FAPSIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL18911084 | 0.94 | FAP (0.43) | FAPSIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL20340686 | 0.93 | FAP (0.46) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23353475 | 0.93 | FAP (0.43) | FAPSIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL20887757 | 0.92 | FAP (0.44) | FAPSIRT2SIRT1SIRT3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885SIRT2 4097/4885SIRT1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.